EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, BMRN:

19 Sep 2025
LAST:

54.36

CHANGE:
 0.78		OPEN:
55.52		HIGH:
55.52		ASK:
94.91		VOLUME:
4.99M
CHG(%):
1.41		PREV:
55.14		LOW:
54.21		BID:
63.38		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Sep 2554.3654.5054.2254.3420K
19 Sep 2555.5255.5254.2154.364.99M
18 Sep 2554.5755.2254.4355.141.52M
17 Sep 2553.8555.1853.6254.372.71M
16 Sep 2553.2054.4253.1553.942.33M
15 Sep 2554.2554.3952.9453.141.83M
12 Sep 2555.6556.0754.0554.091.93M
11 Sep 2554.4655.9554.2055.912.03M
10 Sep 2555.3155.5254.2554.502.15M
09 Sep 2556.2556.5055.1355.691.53M

COMPANY PROFILE

Name:Biomarin Pharmaceuticals
About:BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Sector:Healthcare
Industry:Biotechnology
Address:770 Lindaro Street, San Rafael, CA, United States, 94901
Website:https://www.biomarin.com
CUSIP:09061G101
CIK:0001048477
ISIN:US09061G1013
FIGI:BBG000CZWZ05
LEI:NSLL8ITTRR0J5HEMR848

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:16.91
Price to Book:1.83
Price to Sales:3.59
EBITDA:955.15M
Shares:192.02M
Market Cap:10.438B

TECHNICAL INDICATORS

MA5:54.19
MA10:54.75
MA20:56.46
MA50:57.59
MA100:57.61
MA200:61.71
STO9:36.31
STO14:18.35
RSI14:36.43
WPR14:-79.50
MTM14:-4.73
ROC14:-0.08
ATR:1.56
Week High:56.07
Week Low:52.94
Month High:59.79
Month Low:52.94
Year High:73.51
Year Low:52.93
Volatility:14.90